These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 31181107)

  • 21. Anti-hepatitis B virus activities of α-DDB-FNC, a novel nucleoside-biphenyldicarboxylate compound in cells and ducks, and its anti-immunological liver injury effect in mice.
    Yang Q; Zhao X; Zang L; Fang X; Zhao J; Yang X; Wang Q; Zheng L; Chang J
    Antiviral Res; 2012 Dec; 96(3):333-9. PubMed ID: 23098744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?
    Sheldon J; Ramos B; Toro C; Ríos P; Martínez-Alarcón J; Bottecchia M; Romero M; Garcia-Samaniego J; Soriano V
    Antivir Ther; 2008; 13(1):97-102. PubMed ID: 18389903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-hepatitis B virus activity of swertisin isolated from Iris tectorum Maxim.
    Xu HY; Ren JH; Su Y; Ren F; Zhou YJ; Jiang H; Cheng ST; Zhang CR; Chen J
    J Ethnopharmacol; 2020 Jul; 257():112787. PubMed ID: 32224198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.
    Loggi E; Gitto S; Galli S; Minichiello M; Conti F; Grandini E; Scuteri A; Vitale G; Di Donato R; Cursaro C; Furlini G; Andreone P
    J Clin Virol; 2017 Aug; 93():66-70. PubMed ID: 28654775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
    Coffin CS; Osiowy C; Myers RP; Gill MJ
    J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of hepatitis B virus (HBV) surface-gene variability on markers of replication during treated human immunodeficiency virus-HBV infection in Western Africa.
    Boyd A; Moh R; Maylin S; Abdou Chekaraou M; Mahjoub N; Gabillard D; Anglaret X; Eholié SP; Danel C; Delaugerre C; Zoulim F; Lacombe K;
    Liver Int; 2019 Feb; 39(2):280-289. PubMed ID: 30257068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral effect of Curcuma longa Linn extract against hepatitis B virus replication.
    Kim HJ; Yoo HS; Kim JC; Park CS; Choi MS; Kim M; Choi H; Min JS; Kim YS; Yoon SW; Ahn JK
    J Ethnopharmacol; 2009 Jul; 124(2):189-96. PubMed ID: 19409970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of amantadine and biphenyl dimethyl dicarboxylate on hepatitis B virus in hepatitis B virus replication mice].
    Liu F; Jiang Z; Zhou Q; Yu Y; Meng H; Shi Y
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2014 Apr; 31(2):400-4. PubMed ID: 25039150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High persistence rate of hepatitis B virus in a hydrodynamic injection-based transfection model in C3H/HeN mice.
    Peng XH; Ren XN; Chen LX; Shi BS; Xu CH; Fang Z; Liu X; Chen JL; Zhang XN; Hu YW; Zhou XH
    World J Gastroenterol; 2015 Mar; 21(12):3527-36. PubMed ID: 25834317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HBV cure: why, how, when?
    Levrero M; Testoni B; Zoulim F
    Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity.
    Hu Y; Cheng X; Cao F; Huang A; Tavis JE
    Antiviral Res; 2013 Sep; 99(3):221-9. PubMed ID: 23796982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
    Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
    Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs in the Pipeline for HBV.
    Lopatin U
    Clin Liver Dis; 2019 Aug; 23(3):535-555. PubMed ID: 31266626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of nuclease-resistant ribozymes directed against hepatitis B virus RNA.
    Morrissey DV; Lee PA; Johnson DA; Overly SL; McSwiggen JA; Beigelman L; Mokler VR; Maloney L; Vargeese C; Bowman K; O'Brien JT; Shaffer CS; Conrad A; Schmid P; Morrey JD; Macejak DG; Pavco PA; Blatt LM
    J Viral Hepat; 2002 Nov; 9(6):411-8. PubMed ID: 12431202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precore/core promoter mutations and hepatitis B virus genotype in hepatitis B and C dually infected patients treated with interferon-based therapy.
    Hung CH; Chen CH; Lu SN; Wang JH; Hu TH; Huang CM; Tsai MC; Lee CM
    Antiviral Res; 2012 Jan; 93(1):55-63. PubMed ID: 22061616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus.
    Kiruthika S; Bhat R; Dash R; Rathore AS; Vivekanandan P; Jayaram B
    Sci Rep; 2021 Jun; 11(1):11723. PubMed ID: 34083665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.